CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age12-55
SponsorIndiana University
About this trial
The primary objective of this pilot study is to develop a CGM-based model to predict the progression from prediabetes to diabetes in individuals with cystic fibrosis.
Eligibility criteria
Qualifiers
CF individuals aged 12-55 years.
CF without diabetes or with prediabetes (as defined by OGTT and HbA1c).
Willing to use a continuous glucose monitoring system with compatible smart phone for glucose data collection.
Disqualifiers
Pregnancy.
History of transplant.
Use of immunosuppressant drugs.
Use of oral steroids or any medication known to interfere with glucose.
Trial design
Treatments tested in this trial
- CGM Dynamic Index (CDI)
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov